TrialThe oncologist2026

SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

Adam Brufsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.